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Abstract
Objectives
Understanding the preferences of patients with multiple sclerosis (MS) for disease-modi-
fying drugs and involving these patients in clinical decision making can improve the
concordance between medical decisions and patient values and may, subsequently,
improve adherence to disease-modifying drugs. This study aims first to identify which
characteristics–or attributes–of disease-modifying drugs influence patients´ decisions
about these treatments and second to quantify the attributes’ relative importance among
patients.
Methods
First, three focus groups of relapsing-remitting MS patients were formed to compile a pre-
liminary list of attributes using a nominal group technique. Based on this qualitative
research, a survey with several choice tasks (best-worst scaling) was developed to priori-
tize attributes, asking a larger patient group to choose the most and least important attri-
butes. The attributes’ mean relative importance scores (RIS) were calculated.
PLOS ONE | DOI:10.1371/journal.pone.0164862 November 3, 2016 1 / 16
a11111
OPENACCESS
Citation: Kremer IEH, Evers SMAA, Jongen PJ, van
der Weijden T, van de Kolk I, Hiligsmann M (2016)
Identification and Prioritization of Important
Attributes of Disease-Modifying Drugs in Decision
Making among Patients with Multiple Sclerosis: A
Nominal Group Technique and Best-Worst Scaling.
PLoS ONE 11(11): e0164862. doi:10.1371/journal.
pone.0164862
Editor: Orhan Aktas, Heinrich-Heine-Universitat
Dusseldorf, GERMANY
Received: January 6, 2016
Accepted: October 3, 2016
Published: November 3, 2016
Copyright: © 2016 Kremer et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The authors received no specific funding
for this work.
Competing Interests: During the time of the study
PJ Jongen has received honoraria from Bayer,
Merck, and Teva for contributions to symposia as a
speaker or for consultancy activities. This does not
Results
Nineteen patients reported 34 attributes during the focus groups and 185 patients evalu-
ated the importance of the attributes in the survey. The effect on disease progression
received the highest RIS (RIS = 9.64, 95% confidence interval: [9.48–9.81]), followed by
quality of life (RIS = 9.21 [9.00–9.42]), relapse rate (RIS = 7.76 [7.39–8.13]), severity of
side effects (RIS = 7.63 [7.33–7.94]) and relapse severity (RIS = 7.39 [7.06–7.73]). Sub-
group analyses showed heterogeneity in preference of patients. For example, side effect-
related attributes were statistically more important for patients who had no experience in
using disease-modifying drugs compared to experienced patients (p < .001).
Conclusions
This study shows that, on average, patients valued effectiveness and unwanted effects as
most important. Clinicians should be aware of the average preferences but also that attri-
butes of disease-modifying drugs are valued differently by different patients. Person-cen-
tred clinical decision making would be needed and requires eliciting individual preferences.
Introduction
Multiple sclerosis (MS) is a demyelinating and degenerative disease of the central nervous sys-
tem causing physical and cognitive disabilities.MS occurs as different disease courses [1].
Relapsing-remittingMS (RRMS) is characterized by recurring exacerbations of MS symptoms
(relapses) that recover partially or completely (remission) [1]. Between relapses, the disease
remains stable. Progressive types of MS are characterized by a continuous increase in disability
over time, either from the onset of MS (primary progressive MS) or conversion of RRMS to
secondary progressive MS [1]. When a central nervous system demyelinating event has
occurred that is isolated in time and compatible with the possible future development of MS,
clinically isolated syndrome (CIS) is diagnosed [2]. Thirteen different disease-modifyingdrugs
(DMDs) are currently available in the United States and in Europe to reduce the relapse rate
and disease progression for patients with RRMS and newDMDs are still being developed.
Some of these DMDs are also indicated for the treatment of CIS [3–5]. Adherence to DMD
treatment is problematic, however, ranging from 41% to 88% of doses taken as prescribed [6],
and non-adherence is associated with an increased relapse rate [7].
DMDs differ in their effectiveness, unwanted effects and other characteristics or attributes
[3, 5]. For patients diagnosedwith RRMS or CIS, a decision needs to be made between the
options the patient has, including the option of no DMD treatment. Decisionmaking can be
difficult because it requires comparing different DMD treatment options according to their
specific characteristics or attributes.
Patients with MS have been reported to prefer being actively involved in the decisionmak-
ing about DMDs [8]. Therefore, it is important to inform and involve patients in the decision
to start or not start taking a DMD, and, in case of starting, it is important to choose the type of
DMD that best suits the patient’s preferences and situation. In the shared decisionmaking
approach, the decision is made through a joint process between the physician and the patient.
This entails informing the patient about treatment options and deliberation with the physician
about which treatment would best fit the patient’s preferences [9]. Understanding which DMD
attributes are important according to patients may therefore contribute to the tailoring of
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information for patients in clinical practice and may support the clinical decisionmaking pro-
cess. Effective support of the shared decisionmaking process could improve patient satisfaction
and treatment adherence [10].
Preference research is often used to elicit patients’ preferences for treatment options, i.e. to
determine which attributes of the treatment options are important for patients in decision
making. Patients are asked to state which treatment or treatment attribute they prefer in hypo-
thetical trade-offs between two or more treatments or attributes [11]. Some preference studies
have been conducted on MS patients’ preferences for DMD treatments [12–18] but, to the best
of our knowledge, no study has attempted to identify among patients the full range of attributes
of DMDs in general–regardless of the specific type or administrationmode of the DMD–that
may be of importance in decision-making.Therefore, important attributes of DMDs for deci-
sion making between all available DMDs may have been omitted in the exercises for prioritiza-
tion of the attributes.
The current study aimed to use thorough research methodologies for evaluating patients’
preferences for the full spectrumof DMD attributes that are of importance in the decision
about DMD treatment. More specifically, the study’s objective was twofold. The first objective
was to identify the range of DMD attributes that influence the decision from the patients’ per-
spective. The second objective was to quantify the relative importance of the identified attri-
butes among a large group of patients.
Methods
Consecutive studies were conducted (Fig 1). First, an exploratory literature review and tele-
phone interviewswith healthcare professionals were performed to identify DMD attributes
that may be of importance for decisionmaking in DMD treatment. A full description of the
methods used and results of this exploratory phase is provided in S1 and S2 Texts. Next, patient
focus groups using a nominal group technique were formed to identify attributes and to verify
any additional attributes that were derived from the exploratory phase. A nominal group tech-
nique, as developed by Delbecq and Van de Ven [19, 20], is a structuredmethod for guiding a
group discussion to generate and prioritize ideas for a specific question. The RATS guideline
[21] was used for reporting the methods and results of the nominal group technique, when
appropriate. Finally, a best-worst scaling was conducted to prioritize the attributes according
to a patient sample much larger than the number of patients that participated in the focus
groups. A best-worst scaling is a specificmethod for conducting preference research. Respon-
dents are asked to complete a series of choice tasks in which they have to choose the most and
least important attributes from a selection of 4 or 5 attributes from a master list of attributes
[22]. The advantage of the best-worst scaling over other stated preference research is the ability
to acquire patients’ preferences for a large number of attributes, regardless of the levels of the
attributes. As the best-worst scaling was administered online, design and results of the best-
worst scaling were presented according to the Checklist for Reporting Results of Internet
E-Surveys [23]. The protocols of both the focus groups and the best-worst scaling were submit-
ted to theMedical Ethics Committee of the Academic Hospital Maastricht and Maastricht Uni-
versity, the Netherlands (nr. 14-4-172). The committee concluded that the study did not
qualify for a review according to the Dutch Medical Research Involving Human Subjects Act of
1998 and provided a positive decision for conducting the study. The study was performed in
agreement with the ethical standards laid down in the 1964 Declaration of Helsinki and its
later amendments. All participants gave their written informed consent before participating in
the studies.
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Patient population
Both for the focus groups with nominal group technique and the surveywith the best-worst
scaling, patients were considered eligible for participation if they were diagnosedwith RRMS
or CIS, were 18 years or older, and were willing and able to participate. For the focus groups an
additional criterion was that the participant had experiencewith making a decision about
DMD treatment or had experiencewith taking DMDs. Potential participants were recruited
through advertisements on websites, socialmedia or mailing lists of MS patient organizations.
Patients interested in participating in the focus groups were asked to contact one of the
researchers (I.K.) by phone or e-mail. Based on the respondents’ place of residence, three loca-
tions dispersed over the Netherlands were selected: a hospital in Nijmegen (the eastern part of
the Netherlands) and community centers in Nieuwegein (the middle of the Netherlands) and
Roermond (the southern part of the Netherlands). Patients who fulfilled the inclusion criteria
and were able to travel to one of the selected locations were sent an information leaflet about
the study and a consent form by mail. After a week, the patients were contacted by the first
author to answer any of their questions and to register their participation. After participation
in the focus group, each respondent received a 50 Euro gift card to compensate for any travel
expenses and the time invested. Patients willing to participate in the best-worst scaling were
redirected to the online questionnaire by means of a link in the advertisement or in the e-mail.
After providing information about the purpose and content of the survey, the patients were
informed that by filling out the questionnaire, they gave consent to the use of their answers in
the study. To prevent the same person filling out multiple questionnaires, cookies were placed
on their browser when they submitted their questionnaire. The recruitmentmethod did not
allow us to identify which patients did not choose to participate in the best-worst scaling or the
focus groups.
Focus group with nominal group technique
Design. Focus groups were performed by applying the nominal group technique. The
structuredmethod of a nominal group technique ensures that every participant’s perspective is
included and allows for differences in perspectives [19, 20]. A nominal group technique is
therefore particularly suitable for identifying the full range of important DMD attributes and
has already been used in other studies, e.g. to identify attributes of osteoporotic medications
[24]. Two researchers were present at each focus group to facilitate the group discussion (IK)
and to take notes (IvdK). The nominal group technique consisted of four steps. First, the par-
ticipants were asked to individually answer the following question: “What characteristics of
DMDs do you feel are important to consider when having to make a decision about DMD
Fig 1. Consecutive process of studies.
doi:10.1371/journal.pone.0164862.g001
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treatment?” Second, the participants took turns in reporting attributes until all attributes gener-
ated were written down on a flip-over by the facilitator. This ensured that every participant’s
opinion was elicited, and that they participated in the discussion. Third, the discussionwas
intended to come to an agreement within the group about the meaning and scope of each attri-
bute. The participant that reported the attribute often provided the first description. Other par-
ticipants were given the opportunity to react to this description. If the descriptions were
different or had a broad scope an attribute was split into multiple attributes. If multiple attri-
butes were similar in their meaning, these attributes were combined. This was done upon
agreement of the participants. In the second and third focus group, the discussion was followed
by asking for the participants’ opinions about any additional attributes derived from the
exploratory phase and whether these attributes should be included. Participants were entirely
free to accept or reject the additional attributes. In the final step of each nominal group tech-
nique, participants were asked to select the 10 most important attributes from the list of attri-
butes compiled and rank the top 5. After the third focus group, it was checked whether data
saturation had been reached, i.e. whether any new attributes emerged that had not already
been derived from the previous focus groups or the exploratory phase. Responses during the
nominal group technique were recorded on audio tape so that attribute descriptions could be
transcribed correctly and these tapes were erased afterwards. The anonymity of the respon-
dents was ensured in the transcriptions.
Analyses. An overall list of important DMD attributes for decisionmaking according to
patients was created by comparing the attribute definitions from the three groups to each
other. If from the transcripts of the discussions it appeared that attributes had similar descrip-
tions across the focus groups, then these attributes were combined. The frequencywith which
participants included the attributes in their top 10 and top 5 was calculated. The attributes in
the top 5 were awarded points, from 5 points for the most important attribute to 1 point for the
least important one. Per attribute, the mean importance score was calculated by dividing the
total points awarded per attribute by the total number of patients participating in all focus
groups. Based on the mean importance score and calculated frequencies, an initial ranking of
attributes was made frommost to least important. Attributes that were not included in any of
the participants’ top 10 of most important attributes were excluded from the best-worst
scaling.
Best-worst scaling
Design. Based on the results of the focus groups, a best-worst scaling was developed and
converted to an online questionnaire of 3 pages with 6 questions each, and also contained 2
pages with 4 or 5 questions about the respondent’s demographic and disease characteristics.
All questions had to be filled out before the respondents could proceed to the next page or sub-
mit the questionnaire, but respondents were able to go back to change their answers before sub-
mission. A “don’t know” option was provided for the appropriate demographic questions.
Responses were registered automatically. No data were collected that could be referred back to
the identity of the respondent (e.g. IP-address). The best-worst scaling consisted of 17 unique
choice tasks. Each choice task presented five attributes of the full attribute list as derived from
the focus groups. Each respondent was asked to select the most and least important attributes
for decisionmaking about DMD treatment. The attributes selected by the respondent represent
the attributes that are furthest apart on the importance scale for the individual patient [22].
Additionally, patients were provided the opportunity to list any important DMD attributes
that in their opinion were not included in the best-worst scaling. Fig 2 provides an example of
a choice task.
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A fractional design was created for the best-worst scaling with Sawtooth SSI Web version
8.2.0. This software creates the most efficient design, characterized by orthogonality (the fre-
quency of an attribute paired with other attributes is equal for all attributes), balance (the fre-
quency of attributes occurring in the best-worst scaling is equal), and positional frequency (the
frequency of attributes on the 1st to 5th position in the choice task is equal) and determines
which attributes are presented to the respondent in each choice task. Four best-worst scaling
versions were created. Each attribute was presented 12 or 13 times, was combined at least once
with every other attribute and appeared 2 to 4 times in each position in the choice tasks.
Respondents randomly received 1 of the 4 best-worst scaling versions. The questionnaire was
pilot-tested among researchers (N = 3) and MS patients (N = 3) prior to the start of the study,
which resulted in minor revisions of the instructions. The questionnaire was not found to be
too cognitively burdensome to patients.
Analyses. Questionnaires were filled out from 12 May 2015 to 5 June 2015. Only com-
pleted best-worst scaling questionnaires were included in the analyses. Descriptive statistics
were used to present demographic and disease characteristics of the respondents. Hierarchical
Bayes analysis was performedwith Sawtooth SSI Web version 8.2.0 to estimate the mean rela-
tive importance score per attribute. The raw score, which was obtained with an iterative process
of estimating individual utility scores based on the sample means, was rescaled to a probability
score on a ratio scale. This score represents the attribute’s relative importance for decision
making about DMD treatment according to the respondent. The relative importance scores of
all attributes combined for an individual respondent sum up to 100 [25]. A mean overall rela-
tive importance score was calculated per attribute with its 95% confidence interval. Based on
the mean scores, attributes were ranked frommost to least important for decisionmaking in
DMD treatment. Attributes with a score of 3.7 were regarded as of average importance (100
points divided by 27 attributes). In lack of consensus on the minimal important difference in
relative importance scores, if confidence intervals of two consecutive ranked attributes did not
overlap, we considered them to be of different importance in the decision about DMDs.
The quality of the responses was checked based on the individual’s fit statistic, i.e. if
responses had a fit statistic below 0.247, these were excluded from analyses because this indi-
cates purely random responses to the choice tasks [26]. Subgroup analyses on gender, age, edu-
cation, disease duration, relapse rate, experiencewith DMD, and current and prior DMDs
taken were conducted to explore whether patients’ preferences for DMD attributes differ
according to demographic characteristics, disease characteristics or DMD experience. Sub-
groups for continuous data (age, disease duration) were made according to the median. For
categorical data, subgroups were made based on relevance for comparison (e.g. DMD-naive vs.
Fig 2. Example of a choice task in the best-worst scaling.
doi:10.1371/journal.pone.0164862.g002
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DMD-experienced).Difference in importance scores between subgroups were statistically
tested with an independent t-test for parametric data and the Mann-Whitney test for non-
parametric data using SPSS for Windows version 20. An alpha of .05 and a Bonferroni-adjusted
alpha of .0019 (for 27 comparisons) were used to assess whether differences in RIS of attributes
between subgroups were statistically significant.
Results
Patient population
Table 1 presents the characteristics of the patients that participated in the focus groups and the
best-worst scaling. Three focus groups with a total of 19 RRMS patients took place. Each group
consisted of male and female participants ranging in age, educational level and experiencewith
DMD use. Age was approximately normally distributed with a mean of 46.8 (±8.8) years old.
Thirteen (68.4%) patients had prior experiencewith making a decision about DMDs and six
(31.6%) were considering or reconsidering their DMD options at the time of the focus groups.
Of the 286 people who accessed the survey via the provided link, 193 respondents (67.5%)
started the best-worst scaling exercise and met the inclusion criteria. Of these respondents, 185
people (95.9%) completed the best-worst scaling exercise. The majority of the respondents who
completed the best-worst scaling exercise were female (86.5%); this is somewhat higher than
the DutchMS population of 72% [27]. Of the respondents, 54.1% had completed a higher voca-
tional education or university education.Mean age was 42.1 (±9.6) years, which was approxi-
mately normally distributed, and almost all patients reported a diagnosis of RRMS (98.4%).
Table 1. Patient characteristics: nominal group technique (N = 19) and best-worst scaling (N = 185).
Characteristics Nominal group technique Best-worst scaling
Women n (%) 15 (78.9) 160 (86.5)
Age, mean ± SD (years) 46.8 ± 8.8 42.1 ± 9.6
Educational level n (%)
Lower 7 (36.8) 72 (38.9)
Higher 12 (63.2) 113 (61.1)
Employed
Yes 8 (42.1%) 90 (48.6%)
No 11 (57.9%) 95 (51.4%)
Diagnosis
RRMS n (%) 19 (100) 182 (98.4)
CIS n (%) 0 (0) 3 (1.6)
Duration of diagnosis, mean ± SD (years) 9.5 ± 8.4 6.4 ± 5.9
Relapse rate previous year, n (%) (N = 17) (N = 172)
0 7 (41.2) 63 (36.6)
1 10 (58.8) 109 (63.4)
Currently taking DMD n (%) 15 (78.9) 131 (70.8)
Previously taken DMD n (%) 10 (52.6) 86 (46.5)
Number of prior taken DMD n (%) (N = 184)
1 6 (31.6) 43 (23.4)
2 2 (10.5) 35 (19.0)
3 2 (10.5) 5 (2.7)
4 0 (0) 3 (1.6)
CIS, clinically isolated syndrome; DMD, disease-modifying drug; RRMS, relapsing-remitting multiple sclerosis; SD, standard deviation.
doi:10.1371/journal.pone.0164862.t001
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Twenty-seven (14.6%) patients reported having no experiencewith using DMDs and 131
(70.8%) respondents were currently taking a DMD.
Focus group with nominal group technique
Data saturation was reached in the third focus group because no new attributes emerged. Com-
bining the attribute lists from the three focus groups resulted in 34 DMD attributes that,
according to the patients, were important in decisionmaking about DMD treatment. Based on
the mean importance scores, participants in the focus groups regarded the type of side effects
as most important, followed by effect on disease progression, method of administration, effect
on relapse rate, safety and insurance coverage. Seven attributes were not included in the top 10
by any of the participants (adherence rate, availability of the DMD in the Netherlands, brand
recognition, issuance of DMD, wash-out requirements, shelf life and legal liability). For
descriptions of all DMD attributes, their ranking and mean importance scores, we refer to the
data in S3 Text.
Best-worst scaling
The best-worst scaling survey included 27 attributes. From the list of 34 attributes identified in
the focus groups, seven attributes were excluded because they were not included in the top 10
by any of the participants in the focus groups. All respondents had a fit statistic higher than
0.247 and were therefore all included in the analysis. Hierarchical Bayes analysis showed that
attributes related to effectiveness and unwanted effects were most important for decisionmak-
ing according to patients. Table 2 presents the group average relative importance scores of all
27 attributes with their 95% confidence intervals ranked frommost to least important for deci-
sion making in DMD treatment. The effect on disease progression was ranked as the most
important attribute with a RIS of 9.6 (95% CI 9.5–9.8). The effect on quality of life, defined as
the overall increase in the well-being of a patient as a result of the DMD, was ranked second
(RIS 9.2; 95% CI 9.0–9.4), followed by effect on the relapse rate (RIS 7.8; 95% CI 7.4–8.1), and
severity of side effects (RIS 7.6; 95% CI 7.3–7.9). The severity of side effects scored higher than
safety issues, i.e. common side effects were found to be of more influence on the treatment
decision than risks of life threatening or severely disabling consequences. The most important
attribute not related to beneficial or unwanted effects was influence on life style (RIS 5.3; 95%
CI 4.9–5.7) but this attribute was only half as important as the number one ranked attribute,
effect on disease progression. Other convenience issues with taking DMDs were valued far less:
the RIS for administrationmethod, administration frequency and requiredmonitoring were
1.6 (95% CI 1.2–2.0), 0.7 (95% CI 0.5–0.9) and 0.6 (95% CI 0.4–0.7) respectively. Rankings of
attributes as derived from the focus groups deviate from these results. The convenience issues
mentioned previously were all ranked in the top 10, while the effect on quality of life, plaque
development and severity of side effects were of less importance (Online Resource 3).
One MS patient reported “effect of the DMD on pregnancy or child” as an additional attri-
bute that was not already included in the best-worst scaling. Other attributes that were
reported, such as effect of the DMD on mental well-being and family members, and feelings of
depression or anxiety, were captured in or had considerable overlap with other attributes.
Subgroup analyses showed deviations from the overall importance scores for patients with
certain characteristics. As is presented in Fig 3, patients who had never used a DMD (n = 27)
valued duration, type and severity of side effects significantly higher than did patients who had
DMD experience (n = 157) (respectively U = 946, z = -4.59, p< .001; t(182) = 4.36, p< .001;
U = 863, z = -4.92, p< .001). The patients in this last group had higher relative importance
scores for the effectiveness of the DMD on the relapse rate, relapse severity, plaque development
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and life expectancy compared with DMD-naive patients (respectively U = 1196, z = -3.61,
p< .001; U = 1312, z = -3.16, p = .001; U = 1585, z = -2.09, p = .038; U = 1549, z = -2.23,
p = .026). For attributes of which the relative importance score did not significantly differ
betweenDMD-naive and DMD-experiencedpatients, the results of the analyses are provided in
S1 Table.
Similar differences in the importance of attributes were found for patients who were not
using a DMD at the time of survey administration (n = 54) in comparison with patients using a
DMD (n = 131): attributes concerning effectivenesswere more important in the decision for
patients currently using a DMD, while patients who were not using a DMD valued attributes
related to unwanted effects significantly higher. Although ranked only 16th, the administration
method was more important for patients taking orally administered DMDs (mean RIS = 2.5;
95% CI 1.6, 3.4) in comparison with patients taking parenteral (intramuscular, subcutaneous
or intravenous) DMDs (mean RIS = 1.0; 95% CI 0.6, 1.5), which was a significant difference
(U = 1416, z = -3.28, p = .001). The safety of the DMD was significantlymore important for
patients with a diagnosis of MS longer than 4.6 years compared to patients with shorter disease
durations (U = 3174, z = -3.03, p = .001). Male patients were significantlymore concerned
Table 2. Group average relative importance scores of attributes in decision making as derived from
the best-worst scaling among 185 patients.
Attribute RIS 95% CI lower bound 95% CI upper bound
Effect on disease progression 9.64 9.48 9.81
Effect on quality of life 9.21 9.00 9.42
Effect on relapse rate 7.76 7.39 8.13
Severity of side effects 7.63 7.33 7.94
Effect on the severity of relapses 7.39 7.06 7.73
Effect on current MS symptoms 7.32 7.03 7.60
Effect on plaque development in the brain 7.31 6.94 7.67
Safety 6.04 5.62 6.47
Influence on lifestyle 5.31 4.88 5.73
Type of side effects 5.00 4.60 5.39
Effect on life expectancy 4.81 4.36 5.27
Uncertainty about long-term consequences 4.58 4.18 4.98
Duration of side effects 3.74 3.45 4.02
Pace of effect 3.18 2.87 3.50
Insurance coverage 2.71 2.29 3.12
Interaction with other medication 1.72 1.46 1.99
Method of administration 1.58 1.19 1.97
Mode of action of DMD 0.99 0.81 1.17
Further development of DMD 0.87 0.73 1.00
Total DMD costs 0.86 0.68 1.04
Frequency of administration 0.68 0.48 0.88
Required monitoring 0.55 0.38 0.72
Use of DMD among other MS patients 0.34 0.26 0.42
Ease of travelling 0.29 0.17 0.42
Duration of administration 0.20 0.17 0.24
Composition of DMD 0.18 0.13 0.23
Contact person at pharmaceutical company 0.10 0.06 0.14
CI, confidence interval; DMD, disease-modifying drug; RIS, relative importance score.
doi:10.1371/journal.pone.0164862.t002
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about the influence of DMD use on lifestyle and with the effect on life expectancy in compari-
son with female patients (U = 1366, z = -2.55, p = .011; U = 1468, z = -2.14, p = .032). No
significant differences were found in the importance scores of attributes of higher and lower
educated patients. Results of all subgroup analyses are provided in S1 Fig.
Discussion
The current study aimed to identify the full spectrumof DMD attributes and to quantify their
relative importance in decision-making about DMD treatment according to RRMS and CIS
patients. Patients reported a total of 34 different attributes that might influence their decision.
Quantification of the relative importance showed that, as a group, patients place the most
emphasis on benefits–especiallydisease progression and quality of life–and on unwanted
effects when having to make a decision in DMD treatment, rather than usability issues. The
ranking of the attributes showed that the most important attributes are comparable to the
Fig 3. Attributes’ relative importance score: DMD-naive (n = 27) vs. DMD-experienced patients (n = 157). Attributes are ordered
according to ranking of the overall analysis. The x-axis indicates the relative importance score per attribute with its 95% confidence interval.
* p < .05, ** p < .0019.
doi:10.1371/journal.pone.0164862.g003
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attributes used in other stated preference research [12–18]. Preventing disease progression was
found in previous preference research to be an important attribute of DMDs [12–18] but qual-
ity of life has not yet been reported in these studies. The effect on quality of life–the increase or
decrease in the overall well-being of a patient as a result of the DMD–could be interpreted as a
summarizing attribute, incorporating the DMD’s beneficial effects and burdens into one attri-
bute. This could explain its importance for patients. However, data from high quality random-
ized controlled trials on the effects of DMDs on quality of life are lacking for DMDs that have
been available for the treatment of MS for some time now. It is encouraging that new RCTs
and many observational studies are including quality of life as an outcome measure, since the
effect of the DMD on quality of life is regarded as important information by the patients.
Regarding unwanted effects, the severity of non-life threatening physical and psychological
side effects–essentially, the extent to which these side effects outweigh the desire to treat MS–
was found to be the most influential attribute in decisionmaking. This is in contrast to the
results from the most comprehensive study about preferences for DMD attributes conducted
among a large number of RRMS patients, which found life-threatening or severely disabling
side effects to be the most important attribute and minor side effects to be the least important
[17]. However, this study included four levels for life-threatening side effects denoted as risk of
death or becoming severely disabled (0 out of 1,000; 0.5 out of 1,000; 1 out of 1,000; or 10 out
of 1,000), while common side effects were split into three levels of types of common side effects
(headaches and muscle or joint aches; increased risks of infection; and mood changes). Our
study did not include levels, and therefore these could not influence how patients valued the
attributes, perhaps explaining the differences between the two studies’ findings.
Noteworthy are the relatively low ranking and importance scores of administrationmethod
and administration frequency, ranked 17th and 21st respectively, as derived from the best-worst
scaling, while in the literature these attributes were found to be of substantial importance in
decisionmaking among MS patients [17, 28, 29]. Attributes that were valued more highly than
mode and frequency of administration by patients in our study, such as insurance coverage,
total costs, continuous development of the DMD and interaction with other medication, were
not included in other studies. Moreover, influence on lifestyle was valued relatively highly in
our study. Although it was described to patients as “the extent to which a patient’s habits or
lifestyle have to be adjusted for proper use of the medication, such as the flexibility in time of
administration, restrictions on consuming alcohol, driving, sports, work, etc.”, patients may
have also included administrationmethod and frequency in this attribute, resulting in a higher
ranking in comparison with administrationmethod and frequency.
Subgroup analyses showed heterogeneity in preferences of patients according to different
characteristics. For example, attributes related to unwanted effects were stated to be more influ-
ential in decisionmaking by patients with no prior DMD experience in comparison with
patients who had experiencewith DMD use. These findings reinforce the individuality of pref-
erences and the need to incorporate the individual’s perspective into the clinical decisionmak-
ing process. It underlines the need for shared decisionmaking, as this approach is focused on
supporting patients in developing informed preferences based on objective information [30].
By investigating patients’ preferences about DMD attributes, our study may help to identify
which information patients need about DMDs in order to make an informed decision, there-
fore enabling clinicians to adjust their information provision accordingly to facilitate the pro-
cess of shared decisionmaking and to support the development of informed preferences in
patients. However, clinicians should also take into account that the study results provide guid-
ance for the average patient. As heterogeneity in the results show, different patients could find
different attributes of DMDs important for decisionmaking. Therefore, clinicians should
inform each patient who wants to be involved in the decisionmaking about the pros and cons
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per option based on the patient’s personal preferences. As a result, clinicians should support
the patient to elicit what is important to him or her and adjust the consultation accordingly, i.e.
incorporate the patient’s preference in the decision or delay decisionmaking and empower the
patient with a patient decision aid. A patient decision aid contains concise summaries of the
evidence on important attributes of the treatment options and includes a preference clarifica-
tion method to assess what attributes of the treatment options are of importance for the indi-
vidual patient. A decision aid could therefore support the shared decisionmaking process in
clinical practice [31]. The results of the current study will inform the development of such a
decision aid for MS patients who need to make a decision about DMD treatment.
A strength of our study is the thoroughmethodologyof a nominal group technique followed
by a best-worst scaling used for identification and prioritization of attributes. Using focus
groups with a nominal group technique ensured the direct elicitation of patients’ perspectives
on all important DMD attributes for decisionmaking, whereas prior preference studies focused
only on a selection of attributes and/or relied on literature review and consultations with clini-
cal experts for identification of attributes. Comparing attribute rankings from the nominal
group technique and the best-worst scaling, there were considerable differences. Although data
saturation was achieved in the identification of DMD attributes in the nominal group tech-
nique, we did not aim for data saturation in the ranking of the attributes. Due to variation in
the attributes reported per nominal group technique, not all 34 attributes were included in the
rankings of each focus group, resulting in lower validity of the overall ranking in the nominal
group technique. In addition, the ranking in the nominal group technique was established after
an interactive process of participants discussing the attributes and possibly influencing each
other’s opinion in comparison to the best-worst scaling in which respondents filled out the sur-
vey by themselves. The differences in rankings emphasize the importance of using a quantita-
tive method such as a best-worst scaling for prioritization of the attributes, in addition to
qualitative work on identifying attributes.
Some limitations should be taken into account with the interpretation of the results. We
used patient-centered methodologies for identifying the attributes. However, we cannot
exclude that attributes important for some patients were not included in the study. In the best-
worst scaling, one patient reported an additional attribute to be important: the effect of the
DMD during pregnancy on the unborn child. Although it is generally recommended to discon-
tinue DMD treatment before trying to conceive, treatment with certainDMDs can be contin-
ued in case of highly activeMS [32–36]. Moreover, during DMD treatment patients may
become pregnant inadvertently. A possible reason for omission of this attribute in the best-
worst scalingmay be that the 19 patients questioned in the focus groups and the six healthcare
professionals questioned by interview regarded these risks inherent to safety or side effects.
Another reason for omission by the patients in the focus groups may be that they already had
children or stopped thinking about having children as the average age of patients in the focus
groups was 46.8 years (SD 8.8), meaning that 68% of patients were between 38.0 and 55.6 years
old and ranging from 30 to 68 years old. Actually, only 2 out of 15 women in the focus groups
were between 30 and 35 years of age, the other being older. Thus, the number of women in
child-bearing age was relatively low, which could explain the omission of the attribute regard-
ing pregnancy risks. Furthermore, to be able to include a large number of attributes, the best-
worst scaling did not include attribute levels. The importance scores therefore present the
patients’ preferences for attributes of DMDs in general; preferences for a specificDMD with a
certain attribute level may deviate from the scores obtained in this study. Additionally,
although the recruitmentmethod enabled the inclusion of RRMS and CIS patients from all
regions of the Netherlands, the samples for the focus groups and the best-worst scaling con-
tained a relatively high proportion of women, older participants and more highly educated
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participants in comparison with the average MS patient population in the Netherlands [37]
and may contain patients who are more involved in their diseasemanagement due to our
recruitmentmethod via websites and mailing lists of patient organizations. Patients may there-
fore have a better understanding of what the benefits and risks entail and this could influence
the generalizability of the results. Differences were found betweenmen and women in impor-
tance of attributes, but subgroup analyses revealed no major difference according to age and
level of education of the patient. Moreover, our recruitmentmethod did not enable us to collect
data frommedical records, and therefore diagnosis, disease duration, relapses experienced and
DMD history were self-reported by patients. This may have resulted in incorrect reporting of
medical and sociodemographic characteristics. In addition, the transferability of our findings
to other settings could be uncertain since the health care system and practice could potentially
impact the importance of some attributes, For example, we could expect that the total DMD
costs would be more important in countries where patients have out-of-pocket contributions.
Lastly, the subgroup analyses had an exploratory purpose.We did not aim to recruit a mini-
mum number of patients for each subgroup. Therefore, the difference in importance of attri-
butes according to the subgroups should be interpreted with caution.
In conclusion, this study shows that patients with RRMS and CIS find beneficial and
unwanted effects to be the most important DMD attributes in making decisions about DMD
treatment, more important than usability issues with taking the DMD. The effect on disease
progression and quality of life were the most important attributes. However, this study also rec-
ognizes the heterogeneity in preferences of patients. When having to make a decision about
DMD treatment, clinicians should be aware of what the average patient finds important and
incorporate information on these attributes in the education for the shared decisionmaking
process. However, person-centered clinical decisionmaking requires eliciting the individual
patient’s preferences for DMD treatment at the point of the decision.
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